Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 Maintenance in Metastatic Esophagogastric Cancer
NCT02128243Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Sep 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by AIO-Studien. Primary endpoint: Overall Survival at 12 months. Started Sep 2014; status: completed.
02
Drugs
tegafur
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02128243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128243.